Changes to the Medicaid Drug Rebate Program comments due CMS July 25 CMA id request comments on product data misreporting by pharmaceutical manufacturers, manufacturers obligation to pay unpaid rebate amounts to states due to the misclassification under Inflation Reduction Act
CMS released a Medicaid proposed rule. The proposed rule clarifies and establishes requirements for State fee for-service (FFS) pharmacy reimbursement, including that both ingredient cost reimbursement and professional dispensing fee reimbursement under Medicaid fee for service must be based on pharmacy-established cost data, and that market-based research (such as third-party payments accepted by pharmacies) will not qualify as supporting data.
On May 23, 2023, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule entitled Misclassification of Drugs, Program Administration and Program Integrity Updates.
The Centers for Medicare and Medicaid Services has issued a proposed rule to drive down prescription drug costs in Medicaid by increasing price transparency. The rule would allow CMS to have more insight into what the most expensive drugs on the market actually cost to manufacture and distribute. CMS is not able to mandate that drug manufacturers lower the price of their